Christian Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christian Schmidt has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Kai Rejeski
Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 shared publications - Viktoria Blumenberg
Massachusetts General Hospital 1 Charlestown, MA
4 shared publications - Marion Subklewe
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
3 shared publications - Veit L. Bücklein
LMU University Hospital, München, Germany
3 shared publications - Wolfgang Gerhard Kunz
Department of Radiology, University Hospital, LMU Munich, Munich, Germany
3 shared publications - Michael Ruzicka
Department of Medicine III, Ludwig Maximilian University (LMU) University Hospital, LMU Munich, Munich, Germany
2 shared publications
Latest Publications
- 14 December 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (5) , 1406-1413
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
Purpose Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma. The recently introduced International Metabolic Prognostic Index (IMPI) was shown to improve prognostication in the first-line treatment of large B-cell lymphoma. Here, we investigate the prognostic value of the IMPI for progression-free (PFS) and overall survival (OS) in the setting of CD19 CART. Methods Consecutively treated patients with baseline 18F-FDG PET/CT imaging and follow-up imaging at 30 days after CART were included. IMPI is composed of age, stage, and metabolic tumor volume (MTV) at baseline and was compared with the International Prognostic Index (IPI). Both indices were grouped into quartiles, as previously described for IPI. In addition, the continuous IMPI was subdivided into tertiaries for better separation of risk groups. Overall response rate (ORR), depth of response (DoR), and PFS were determined based on Lugano criteria. Proportional Cox regression analysis studied association of IMPI and IPI with PFS and OS. Results Thirty-nine patients were included. The IPI was 1 in 23%, 2 in 21%, 3 in 26%, 4 in 21%, and 5 in 10% of the patients. IMPIlow risk, IMPIintermediate risk, and IMPIhigh risk patients had 30-day ORR of 69%, 62%, and 62% and 30-day DoR of − 67%, − 66%, and − 54% with a PFS of 187 days, 97 days, and 87 days, respectively. ORR and DoR showed no correlation with lower IMPI (r = 0.065, p = 0.697). Dividing patients into three risk groups showed a significant trend for PFS stratification (p = 0.030), while IPI did not (p = 0.133). Neither IPI nor IMPI yielded a significant association with OS after CART (both p > 0.05). Conclusion In the context of CART, the IMPI yielded prognostic value regarding PFS estimation. In contrast with IMPI in the first-line DLBCL setting, we did not observe a significant association of IMPI at baseline with OS after CART.
- 14 December 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (5) , 1406-1413
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
Purpose Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma. The recently introduced International Metabolic Prognostic Index (IMPI) was shown to improve prognostication in the first-line treatment of large B-cell lymphoma. Here, we investigate the prognostic value of the IMPI for progression-free (PFS) and overall survival (OS) in the setting of CD19 CART. Methods Consecutively treated patients with baseline 18F-FDG PET/CT imaging and follow-up imaging at 30 days after CART were included. IMPI is composed of age, stage, and metabolic tumor volume (MTV) at baseline and was compared with the International Prognostic Index (IPI). Both indices were grouped into quartiles, as previously described for IPI. In addition, the continuous IMPI was subdivided into tertiaries for better separation of risk groups. Overall response rate (ORR), depth of response (DoR), and PFS were determined based on Lugano criteria. Proportional Cox regression analysis studied association of IMPI and IPI with PFS and OS. Results Thirty-nine patients were included. The IPI was 1 in 23%, 2 in 21%, 3 in 26%, 4 in 21%, and 5 in 10% of the patients. IMPIlow risk, IMPIintermediate risk, and IMPIhigh risk patients had 30-day ORR of 69%, 62%, and 62% and 30-day DoR of − 67%, − 66%, and − 54% with a PFS of 187 days, 97 days, and 87 days, respectively. ORR and DoR showed no correlation with lower IMPI (r = 0.065, p = 0.697). Dividing patients into three risk groups showed a significant trend for PFS stratification (p = 0.030), while IPI did not (p = 0.133). Neither IPI nor IMPI yielded a significant association with OS after CART (both p > 0.05). Conclusion In the context of CART, the IMPI yielded prognostic value regarding PFS estimation. In contrast with IMPI in the first-line DLBCL setting, we did not observe a significant association of IMPI at baseline with OS after CART.
- 17 August 2021
- Published by S. Karger AG in Karger Kompass Onkologie
- Vol. 8 (3) , 159-165
Schwere Candida-glabrata-Pankolitis und letale Aspergillus-fumigatus-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie – ein Fallbericht
Hintergrund: Eine lang andauernde Myelosuppression ist ein wichtiges, bisher jedoch unzureichend beschriebenes unerwünschtes Ereignis nach einer gegen CD19 gerichteten CAR-T-Zell-Transfusion. Die resultierende Neutropenie und multifaktorielle Immunsuppression können schwere Infektionskomplikationen begünstigen. Vorstellung des Falls: Wir beschreiben den klinischen Verlauf eines 59-jährigen Patienten mit rezidivierendem/refraktärem DLBCL, der mit Axicabtagen-Ciloleucel (Axi-Cel) behandelt wurde. Der Patient entwickelte ein CRS vom ASTCT-Grad I und ICANS vom Grad IV, was eine Verlegung in die neurologische Intensivstation und anhaltende Gabe hochdosierter Kortikosteroide und anderer Immunsuppressiva erforderlich machte. Die Neutropenie war hochgradig (NEU Candida-glabrata-Pankolitis. Schlussfolgerungen: Dieser Fall unterstreicht das erhöhte Risiko tödlicher Infektionskomplikationen bei Patienten mit sehr schwerer und lang andauernder Zytopenie nach einer CAR-T-Zell-Therapie. Wir beschreiben hier einen seltenen Fall einer C.-glabrata-Pankolitis im Zusammenhang mit einer multifaktoriellen Immunsuppression. Unser Patient erlag zwar letztlich einer letalen Mykose, doch die autologe Stammzell-Boosterung vermochte die Hämatopoese anzuregen und könnte somit eine wichtige Behandlungsstrategie bei DLBCL-Patienten mit CAR-T-Zell-assoziierter Knochenmarkaplasie sein, denen zuvor Stammzellen entnommen wurden.
- 17 August 2021
- Published by S. Karger AG in Karger Kompass Onkologie
- Vol. 8 (3) , 159-165
Schwere Candida-glabrata-Pankolitis und letale Aspergillus-fumigatus-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie – ein Fallbericht
Hintergrund: Eine lang andauernde Myelosuppression ist ein wichtiges, bisher jedoch unzureichend beschriebenes unerwünschtes Ereignis nach einer gegen CD19 gerichteten CAR-T-Zell-Transfusion. Die resultierende Neutropenie und multifaktorielle Immunsuppression können schwere Infektionskomplikationen begünstigen. Vorstellung des Falls: Wir beschreiben den klinischen Verlauf eines 59-jährigen Patienten mit rezidivierendem/refraktärem DLBCL, der mit Axicabtagen-Ciloleucel (Axi-Cel) behandelt wurde. Der Patient entwickelte ein CRS vom ASTCT-Grad I und ICANS vom Grad IV, was eine Verlegung in die neurologische Intensivstation und anhaltende Gabe hochdosierter Kortikosteroide und anderer Immunsuppressiva erforderlich machte. Die Neutropenie war hochgradig (NEU Candida-glabrata-Pankolitis. Schlussfolgerungen: Dieser Fall unterstreicht das erhöhte Risiko tödlicher Infektionskomplikationen bei Patienten mit sehr schwerer und lang andauernder Zytopenie nach einer CAR-T-Zell-Therapie. Wir beschreiben hier einen seltenen Fall einer C.-glabrata-Pankolitis im Zusammenhang mit einer multifaktoriellen Immunsuppression. Unser Patient erlag zwar letztlich einer letalen Mykose, doch die autologe Stammzell-Boosterung vermochte die Hämatopoese anzuregen und könnte somit eine wichtige Behandlungsstrategie bei DLBCL-Patienten mit CAR-T-Zell-assoziierter Knochenmarkaplasie sein, denen zuvor Stammzellen entnommen wurden.
- Open Access
- 17 June 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (S2)
EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
- 17 June 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (S2)
Open AccessEXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 41-42
Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies
Introduction: Genetically engineered CD19-specific CAR T-lymphocytes have emerged as a powerful new class of immunotherapeutic agents in relapsed/refractory B-cell malignancies. However, their utility is hampered by unique toxicities including prolonged cytopenias that can predispose for severe infectious complications. Here, we evaluate predictive markers of hematotoxicity in patients treated in the real-world setting. Methods: To define the incidence and nature of CAR T-cell associated hematotoxicity, we performed a retrospective chart review across three German academic hospitals (LMU Munich, Tübingen, Hamburg-Eppendorf). Between January 2019 and June 2020, a total of 69 patients (58 r/r B-NHL, 11 BCP-ALL) were studied following treatment with the commercial CD19-specific CAR T-cell products Axi-cel (n=43) or Tisa-cel (n=26). The relative impact of baseline (=prior to lymphodepletion) demographic, laboratory and clinical characteristics on hematotoxicity was analyzed by uni- & multivariate analysis using the following primary endpoint: duration of clinically significant neutropenia - defined as an ANC Results: In this heavily pre-treated cohort, the incidence of severe neutropenia (ANC Figure 1): Platelet Count (r = -0.45, P=0.0001), Hemoglobin (r = - 0.33, P=0.006), ANC (r = - 0.28, P=0.02), C-reactive Protein (r = +0.35, P=0.004), Ferritin (r = +0.52, P= Conclusions: Profound and prolonged neutropenia was common in our study cohort. This included cases of severe, G-CSF-refractory bone marrow aplasia. The identified predictive markers point toward a multifactorial model of pathogenesis for CAR T-cell associated hematotoxicity. They include markers of impaired hematopoietic reserve (e.g. low baseline PLT count, Hemoglobin, ANC), inflammatory state (e.g. hyperferritinemia, elevated CRP), and tumor microenvironment (e.g. BM infiltration). These findings carry important implications for both risk-stratification and the development of predictive clinical tools. The identified factors are currently being validated in an independent patient cohort and prospective validation is ongoing.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 41-42
Open AccessIdentification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies
Introduction: Genetically engineered CD19-specific CAR T-lymphocytes have emerged as a powerful new class of immunotherapeutic agents in relapsed/refractory B-cell malignancies. However, their utility is hampered by unique toxicities including prolonged cytopenias that can predispose for severe infectious complications. Here, we evaluate predictive markers of hematotoxicity in patients treated in the real-world setting. Methods: To define the incidence and nature of CAR T-cell associated hematotoxicity, we performed a retrospective chart review across three German academic hospitals (LMU Munich, Tübingen, Hamburg-Eppendorf). Between January 2019 and June 2020, a total of 69 patients (58 r/r B-NHL, 11 BCP-ALL) were studied following treatment with the commercial CD19-specific CAR T-cell products Axi-cel (n=43) or Tisa-cel (n=26). The relative impact of baseline (=prior to lymphodepletion) demographic, laboratory and clinical characteristics on hematotoxicity was analyzed by uni- & multivariate analysis using the following primary endpoint: duration of clinically significant neutropenia - defined as an ANC Results: In this heavily pre-treated cohort, the incidence of severe neutropenia (ANC Figure 1): Platelet Count (r = -0.45, P=0.0001), Hemoglobin (r = - 0.33, P=0.006), ANC (r = - 0.28, P=0.02), C-reactive Protein (r = +0.35, P=0.004), Ferritin (r = +0.52, P= Conclusions: Profound and prolonged neutropenia was common in our study cohort. This included cases of severe, G-CSF-refractory bone marrow aplasia. The identified predictive markers point toward a multifactorial model of pathogenesis for CAR T-cell associated hematotoxicity. They include markers of impaired hematopoietic reserve (e.g. low baseline PLT count, Hemoglobin, ANC), inflammatory state (e.g. hyperferritinemia, elevated CRP), and tumor microenvironment (e.g. BM infiltration). These findings carry important implications for both risk-stratification and the development of predictive clinical tools. The identified factors are currently being validated in an independent patient cohort and prospective validation is ongoing.
- 17 January 2020
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 37 (3) , 271-273
Breach Rhythm May Be Suppressed as a Form of Todd's Paralysis
Summary: This case report will provide further evidence for the fact that breach rhythm is not the effect of a bone abnormality only. We present the case of an 84–year-old woman, who had a craniotomy 14 month before admission to our emergency department with a focal inhibitory status epilepticus. Even after clinical recovery, electroencephalography revealed frequent subclinical seizure patterns. When seizure activity was suppressed by anticonvulsive medication with levetiracetam, breach rhythm appeared. Breach rhythm develops usually some months after craniotomy and therefore should have been established in our patient at the time of admission. Therefore, it is reasonable to assume that it was in some way suppressed by the seizure activity in our primary EEG recordings. The appearance of the breach rhythm after the complete suppression of seizure activity by antiepileptic drug treatment shows that breach rhythm is not purely the result of a skull defect but is related to the functional state of the brain tissue beneath.
- 17 January 2020
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 37 (3) , 271-273
Breach Rhythm May Be Suppressed as a Form of Todd's Paralysis
Summary: This case report will provide further evidence for the fact that breach rhythm is not the effect of a bone abnormality only. We present the case of an 84–year-old woman, who had a craniotomy 14 month before admission to our emergency department with a focal inhibitory status epilepticus. Even after clinical recovery, electroencephalography revealed frequent subclinical seizure patterns. When seizure activity was suppressed by anticonvulsive medication with levetiracetam, breach rhythm appeared. Breach rhythm develops usually some months after craniotomy and therefore should have been established in our patient at the time of admission. Therefore, it is reasonable to assume that it was in some way suppressed by the seizure activity in our primary EEG recordings. The appearance of the breach rhythm after the complete suppression of seizure activity by antiepileptic drug treatment shows that breach rhythm is not purely the result of a skull defect but is related to the functional state of the brain tissue beneath.
- 11 October 2012
- Published by Springer Nature in Der Chirurg
- Vol. 83 (10) , 866-874
Osteoporotische Wirbelkörperfrakturen der thorakolumbalen Wirbelsäule
Thorakolumbale Wirbelkörperfrakturen können bei entsprechender Osteoporose bereits ohne relevantes Unfallereignis auftreten. Initial steht die korrekte Diagnostik, das Erkennen frischer Wirbelkörperläsionen unter Beurteilung der Stabilität, im Vordergrund. Ziel der Therapie ist es, eine möglichst rasche und schmerzarme Mobilisation unter Erhalt des physiologischen Wirbelsäulenalignments zu erreichen. Dementsprechend besitzt bei entsprechend stabiler Frakturmorphologie das konservative Management oberste Priorität. Im Falle von Schmerzpersistenz sowie Nachsinterungstendenz kommen minimal-invasive Zementaugmentationsverfahren zum Einsatz. Instabile Frakturformen benötigen demgegenüber eine 360°-Versorgung im Sinne einer Hybridstabilisierung. Insbesondere bei Revisionseingriffen sind aber aufwendige und langstreckige Verfahren erforderlich. Dabei sollte die Instrumentierung unbedingt über den Scheitelpunkt der Kyphose hinausgehen. In cases of severe osteoporosis vertebral body fractures of the thoracolumbar spine can occur without any relevant trauma. Initially, a standardized diagnostic algorithm is recommended to detect acute vertebral body fractures and to be able to interpret the individual fracture stability. Aim of the therapy is to assure a relatively pain-free mobilization while maintaining vertebral spine alignment. A conservative therapy concept is initiated in patients with stable fractures. In cases of persistent pain, reduced mobility or increased kyphotic misalignment minimally invasive cement augmented therapy strategies are chosen. In cases of unstable fracture morphology a more complex therapy concept has to be chosen such as hybrid stabilization. A great deal of experience is needed for revision surgery. In such cases reconstructive, multi-segmental techniques might be necessary and the instrumentation should surpass the apex of kyphosis.
- 11 October 2012
- Published by Springer Nature in Der Chirurg
- Vol. 83 (10) , 866-874
Osteoporotische Wirbelkörperfrakturen der thorakolumbalen Wirbelsäule
Thorakolumbale Wirbelkörperfrakturen können bei entsprechender Osteoporose bereits ohne relevantes Unfallereignis auftreten. Initial steht die korrekte Diagnostik, das Erkennen frischer Wirbelkörperläsionen unter Beurteilung der Stabilität, im Vordergrund. Ziel der Therapie ist es, eine möglichst rasche und schmerzarme Mobilisation unter Erhalt des physiologischen Wirbelsäulenalignments zu erreichen. Dementsprechend besitzt bei entsprechend stabiler Frakturmorphologie das konservative Management oberste Priorität. Im Falle von Schmerzpersistenz sowie Nachsinterungstendenz kommen minimal-invasive Zementaugmentationsverfahren zum Einsatz. Instabile Frakturformen benötigen demgegenüber eine 360°-Versorgung im Sinne einer Hybridstabilisierung. Insbesondere bei Revisionseingriffen sind aber aufwendige und langstreckige Verfahren erforderlich. Dabei sollte die Instrumentierung unbedingt über den Scheitelpunkt der Kyphose hinausgehen. In cases of severe osteoporosis vertebral body fractures of the thoracolumbar spine can occur without any relevant trauma. Initially, a standardized diagnostic algorithm is recommended to detect acute vertebral body fractures and to be able to interpret the individual fracture stability. Aim of the therapy is to assure a relatively pain-free mobilization while maintaining vertebral spine alignment. A conservative therapy concept is initiated in patients with stable fractures. In cases of persistent pain, reduced mobility or increased kyphotic misalignment minimally invasive cement augmented therapy strategies are chosen. In cases of unstable fracture morphology a more complex therapy concept has to be chosen such as hybrid stabilization. A great deal of experience is needed for revision surgery. In such cases reconstructive, multi-segmental techniques might be necessary and the instrumentation should surpass the apex of kyphosis.
- 17 July 2010
- Published by Springer Nature in Der Anaesthesist
- Vol. 59 (8) , 717-726
Verbesserung der Teamkompetenz im OP
- 17 July 2010
- Published by Springer Nature in Der Anaesthesist
- Vol. 59 (8) , 717-726
Verbesserung der Teamkompetenz im OP
- 1 September 1999
- Published by Georg Thieme Verlag KG in Laryngo-Rhino-Otologie
- Vol. 78 (09) , 475-480
Konzept zur Messung der Lebensqualität bei Patienten mit chronischer Sinusitis
Hintergrund: Benninger hat 1997 den krankheits-spezifischen „Rhinosinusitis Disability Index” (RSDI) für Patienten mit rhinosinusitischen Beschwerden entwickelt, der die Kriterien nicht nur der sogenannten „face-validity”, sondern auch der Konstrukt-Inhalts-Validität, der Sensitivität und der Reliabilität für den amerikanischen Lebensraum erfüllt. Das Ziel dieser Arbeit ist die Vorstellung eines Konzepts, das ein Meßinstrument der LQ für den deutschsprachigen Raum darstellen könnte. Methode: Der Fragebogen „Rhinosinusitis-Behinderungs-Index” (RSBI) beinhaltet 30 Fragen, mit denen die 5 Dimensionen der LQ erfaßt werden. Darüber hinausgehend wird ein standardisierter Aufnahmebogen mit Angaben zur speziellen Anamnese und den Befunden der Untersuchung verwendet. Das Ausma&ß der Beschwerden und Befunde kann damit detailliert erfaßt werden. Die Auswertung erfolgt sowohl nach Fragekomplex, aber auch für die einzelnen Items gesondert. Die Auswirkung einer Behandlung auf die LQ kann damit über die Summe der spezifischen Scores und insgesamt durch den Total-Score gemessen werden. Das Konzept der Studie beinhaltet eine prospektive Erhebung sowohl vor, als auch nach der Intervention. Schlußfolgerungen: Ein Nachteil des amerikanischen RSDI ist das Fehlen eines klinischen Symptomenkatalogs, der die Korrelation klinischer Faktoren zuläßt. Deshalb haben wir dem erarbeiteten RSBI einen ausführlichen Symptom- und Behandlungsbogen zugefügt. Eine multivariate Analyse der Lebensqualität ist damit in Abhängigkeit von verschiedenen Krankheits- und Behandlungsparametern möglich. Background: In 1997, Benninger developed the Rhinosinusitis Disability Index (RSBI) for patients who suffered from chronic Sinusitis. Its content related validity and construct related validity were established, as were its sensitivity and reliability. The aim of our study is to introduce a concept to measure quality of life in these patients according to circumstances prevalent in Germany. Methods: The questionnaire (Rhinusitis-Beeinträchtigungs-Index, RSBI) contains 30 questions that describe the 5 aspects of quality of life. Moreover we used a standardized data sheet to acquire further information about history and diagnostic results. Using this method it is possible to specifity more precisely the patients current complaints and condition. Evaluation is possible according to complex of questions as well as simple items. The influence of treatment on quality of life can be measured as the sumof the specific scores and is expressed comprehensively in the total score. The concept of the study includes a prospective inquiry as well as before and after surgical Intervention. Conclusion: A disadvantage of the American RSDI is that the clinical Symptoms are not described in a detailed catalogue which allows the correlation of the clinical factors. Therefore we added a detailed questionnaire concerning the clinical Symptoms and the individual treatment of the patient (RSBI). That permits comprehensive analysis of quality of life as it relates to different aspects of disease and different strategies in treatment.
- 1 September 1999
- Published by Georg Thieme Verlag KG in Laryngo-Rhino-Otologie
- Vol. 78 (09) , 475-480
Konzept zur Messung der Lebensqualität bei Patienten mit chronischer Sinusitis
Hintergrund: Benninger hat 1997 den krankheits-spezifischen „Rhinosinusitis Disability Index” (RSDI) für Patienten mit rhinosinusitischen Beschwerden entwickelt, der die Kriterien nicht nur der sogenannten „face-validity”, sondern auch der Konstrukt-Inhalts-Validität, der Sensitivität und der Reliabilität für den amerikanischen Lebensraum erfüllt. Das Ziel dieser Arbeit ist die Vorstellung eines Konzepts, das ein Meßinstrument der LQ für den deutschsprachigen Raum darstellen könnte. Methode: Der Fragebogen „Rhinosinusitis-Behinderungs-Index” (RSBI) beinhaltet 30 Fragen, mit denen die 5 Dimensionen der LQ erfaßt werden. Darüber hinausgehend wird ein standardisierter Aufnahmebogen mit Angaben zur speziellen Anamnese und den Befunden der Untersuchung verwendet. Das Ausma&ß der Beschwerden und Befunde kann damit detailliert erfaßt werden. Die Auswertung erfolgt sowohl nach Fragekomplex, aber auch für die einzelnen Items gesondert. Die Auswirkung einer Behandlung auf die LQ kann damit über die Summe der spezifischen Scores und insgesamt durch den Total-Score gemessen werden. Das Konzept der Studie beinhaltet eine prospektive Erhebung sowohl vor, als auch nach der Intervention. Schlußfolgerungen: Ein Nachteil des amerikanischen RSDI ist das Fehlen eines klinischen Symptomenkatalogs, der die Korrelation klinischer Faktoren zuläßt. Deshalb haben wir dem erarbeiteten RSBI einen ausführlichen Symptom- und Behandlungsbogen zugefügt. Eine multivariate Analyse der Lebensqualität ist damit in Abhängigkeit von verschiedenen Krankheits- und Behandlungsparametern möglich. Background: In 1997, Benninger developed the Rhinosinusitis Disability Index (RSBI) for patients who suffered from chronic Sinusitis. Its content related validity and construct related validity were established, as were its sensitivity and reliability. The aim of our study is to introduce a concept to measure quality of life in these patients according to circumstances prevalent in Germany. Methods: The questionnaire (Rhinusitis-Beeinträchtigungs-Index, RSBI) contains 30 questions that describe the 5 aspects of quality of life. Moreover we used a standardized data sheet to acquire further information about history and diagnostic results. Using this method it is possible to specifity more precisely the patients current complaints and condition. Evaluation is possible according to complex of questions as well as simple items. The influence of treatment on quality of life can be measured as the sumof the specific scores and is expressed comprehensively in the total score. The concept of the study includes a prospective inquiry as well as before and after surgical Intervention. Conclusion: A disadvantage of the American RSDI is that the clinical Symptoms are not described in a detailed catalogue which allows the correlation of the clinical factors. Therefore we added a detailed questionnaire concerning the clinical Symptoms and the individual treatment of the patient (RSBI). That permits comprehensive analysis of quality of life as it relates to different aspects of disease and different strategies in treatment.